Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Presentations at ID week
View:
Post by scarlet1967 on Oct 09, 2023 12:09pm

Presentations at ID week

https://www.linkedin.com/posts/theratechnologies-inc_idweek-idweek2023-hiv-activity-7117162365468430336-T2lY?utm_source=share&utm_medium=member_ios

First presentation will be by Dr. Lindsay Fourman who has been involved in many studies/publications relating to Tesamorelin's various medical benefits.

 

"Dr. Fourman is an endocrinologist and Assistant Professor of Medicine at Massachusetts General Hospital and Harvard Medical School. She has a robust clinical research program geared toward elucidating mechanisms and treatment strategies for cardiometabolic disease. Her research portfolio includes studies focused on use of tesamorelin to treat nonalcoholic fatty liver disease among people with HIV as well as the investigation of long-term health outcomes among individuals with perinatal HIV exposure. Clinically, Dr. Fourman is Associate Director of MGH Lipid and Metabolism Associates, which serves as a center of excellence for the management of patients with HIV-related cardiometabolic disorders such as abdominal fat accumulation. She also directs the MGH Metabolic Disorders Conference, which melds clinical experience with scientific literature to develop best practices for various lipid and metabolic diseases."
 

She also will be presenting about managing central fat accumulation in PLWH together with Dr. Claudia Martorell.
 

"Dr. Claudia Martorell is a Board-Certified Infectious Disease Specialist and Clinical Investigator. She presently serves as the Director and Principal Investigator of The Research Institute in Springfield, Massachusetts. Clinical interests include HIV, Hepatitis C, and Hepatitis B, Sexually Transmitted Infections, HIV Prevention, Substance Use and Transgender Care. 
Dr. Martorell earned her medical degree from The University of Puerto Rico School of Medicine in 1998. She completed an Internal Medicine Residency and Infectious Disease Fellowship at Baystate Medical Center. She earned a Masters of Public Health in Health Care Management from Harvard University School of Public Health, and completed a Fellowship in Health Policy and Minority Health Policy from Harvard Medical School. 
She is Nationally recognized for her leadership role in HIV and HCV research, and clinical treatment in Minority Populations. She has contributed and published articles on HIV, HCV, PreP and Health Care Disparities. Dr. Martorell is also a National trainer on HIV, Hepatitis C, and HIV Prevention. Dr. Martorell has received multiple awards, including the 2007 Severo Ochoa Award for outstanding contribution to eradicating HIV/AIDS in the minority community, and was the recipient of the 2004 American Medical Association Foundation Excellence in Medicine Award."

IDWeek 2023

The third presentation is relating to viral suspension among heavily treated HIV patients. 

https://idweek2023.eventscribe.net/index.asp?presTarget=2382323

Comment by Trogarzon on Oct 09, 2023 2:24pm
When will all this science ever translate into sharholder value... like what 400M invested by Thera and the NIH since inception... like Greenspoon, Loomba and others calling it a Nash drug and what... 50M market cap and no Nash value... like 4 45 feet trailer of paperwork, 10 years of safety data.. F8 now will give it 10 more years +... like why are we the only stupidos in the wolrd seing this ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities